Opportunities Preloader

Please Wait.....

Report

IVD Quality Control Market Assessment, By Source [Plasma, Whole Blood, Urine], By Product [Quality Control Products, Data Management Solutions, Quality Assessment Services], By Application [Oncology, Cardiology, Neurology, Infectious Diseases, Autoimmune Disorders, Others], By Technique [Molecular Diagnostics, Coagulation/Hemostasis, Hematology, Microbiology, Immunochemistry/Immunoassay, Clinical Chemistry/Biochemistry, Others], By End-user [Hospitals and Clinics, Diagnostic Laboratories, IVD Manufacturers, CROs, Others], By Region, Opportunities and Forecast, 2017-2031F

Market Report I 2024-07-16 I 223 Pages I Market Xcel - Markets and Data

Global IVD quality control market is projected to witness a CAGR of 4.77% during the forecast period 2024-2031F, growing from USD 1.32 billion in 2023 to USD 1.91 billion in 2031F. Various factors shape the global IVD quality control market, including an increased focus on developing new and innovative products, increased integration of advanced technologies, rise in demand for immunoassay products, increased popularity of data management solutions, and dominance of North America.
Several factors are controlling the global IVD quality control market, including fostering innovations and developing new products. Manufacturers are always trying to create new and better disposable surgical instruments that will increase surgical efficiency, patient safety, and affordability. This requires investigating cutting-edge components, styles, and features to satisfy the changing demands of the medical field. The global IVD quality control market is integrating cutting-edge technology, including artificial intelligence, data management systems, and automation. These technological developments enhance the precision, effectiveness, and accessibility of quality control procedures in diagnostic testing.
The global IVD quality control market is anticipated to be dominated by the immunoassay/immunochemistry segment. This is because an increasing variety of immunoassay tests are available, which offer quick, easy, and precise findings for target identification and quantification. Since they make data storage, processing, and reporting more efficient, data management systems are becoming increasingly popular in the global IVD quality control industry. These technologies facilitate data integrity, increase overall operational efficiency, and simplify quality control procedures for laboratories.
For example, a global leader in clinical diagnostic products and life science research, Bio-Rad Laboratories, Inc., announced in September 2023 the introduction of its PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers, intended to facilitate polymerase chain reaction (PCR) applications in basic and translational research, process development, and quality control. The newest models in Bio-Rad's traditional PCR heat cyclers lineup are the PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers. The PTC Tempo Thermal Cyclers are designed with an updated, user-friendly interface and adaptable connectivity options, including the ability to monitor data on the BR.io cloud platform to streamline protocol administration.
Increased Focus on Developing PCR Tests in the Market
The global IVD quality control market is witnessing an increased focus on the development of PCR tests. Applications and methods for polymerase chain reaction have been created, refined, and employed in the last several years for a variety of clinical fields. The creation of quality standards for these new PCR methods has been necessary to comply with both good laboratory practice (GLP) and (inter)national guidelines, as is the case with any "in-house" assay whose results impact clinical decision-making. Quality standards have previously been established for "classical" diagnostic tests like ELISAs and culture-based assays, and there are also established recommendations for both quality assurance and quality control for new PCR-based assays that are constantly being developed and improved.
For example, the GENE-UP BREWPRO Yeast Slurry (YS) is a novel diagnostic quality control PCR test that was introduced in May 2024 by bioMerieux, Inc., a global leader in in vitro diagnostics. Its purpose is to precisely identify impurities in raw yeast materials and yeast propagations to guarantee fermentation of the highest caliber. The solution, which was created in partnership with White Labs, has specialized targets designed specifically for yeast slurries and an optimized sample prep with higher sensitivity. Present-day brewing industry quality control test kits are made to identify possible spoilers in the final product rather than in the yeast slurries themselves.
Increased Integration of Advanced Technologies is Driving the Market
Innovation is essential for improving quality control, and the tremendous transition in the diagnostics industry is bolstering the growth of the global IVD quality control market. The diagnosis procedure is being completely transformed by cutting-edge technology, including automation, machine learning, and artificial intelligence. These developments have the potential to increase the precision, effectiveness, and dependability of quality control procedures, producing test results that are more reliable and consistent. The diagnostics industry's quality control procedures have seen a substantial transformation because of the incorporation of Internet of Things (IoT) technologies. Diagnostic tools with IoT capabilities may continually track several variables, including equipment performance, humidity, and temperature. Proactive quality control procedures are made possible by the quick detection of any deviations from ideal operating conditions made possible by this real-time data collection.
For example, Bio-Rad Laboratories Inc. revealed in August 2023 that they will leverage AWS Systems Manager to build an Internet of Things device that will enhance their Next-Generation Quality Control Informatics Solution. AWS Systems Manager is a comprehensive and secure resource management tool that can be used in hybrid and multi-cloud scenarios. Without requiring any extra IT support, it connects to the instrument, the lab information system, middleware, and other software through an edge device that serves as a bridge between the lab and the cloud.
The Rise in Demand for Immunoassay Products is Boosting Market Growth
Immunoassay products are an important part of the global IVD quality control market. IVD kits and reagent variance are evaluated and tracked using immunoassay-based quality control tools. Any variations in performance can be found and fixed by comparing several IVD products to standardized immunoassay controls. Immunoassay-based quality control products can be used to identify the cause of problems in diagnostic testing. Potential causes of error, such as reagent quality, instrument performance, or operator technique, can be found and fixed by comparing results from control samples to predicted values.
For instance, Siemens Healthineers AG introduced Atellica CI Analyzer, a small testing equipment designed to address lab problems, in July 2023. With its unique features, the Atellica CI Analyzer is carefully built to maximize downtime and boost lab productivity and profitability. Labs can provide more consistent sample turnaround times thanks to automated maintenance and quality control scheduling, micro-volume aspiration, and random-access sampling. The independence of the immunoassay and chemistry engines ensures that throughput is unaffected if one of them needs to stop.
Data Management Solutions are Popular in the Market
Data management solutions offer a centralized platform for storing, organizing, and managing all data about quality control procedures in the IVD industry. In this way, a single source for quality control data is produced, incorporating information from several diagnostic devices, laboratory information systems (LIS), and other locations. Data management systems offer safe data storage, access controls, and audit trails to guarantee the accuracy and traceability of quality control data. Real-time monitoring of quality control parameters, including test results, reagent stability, and equipment performance, can be facilitated by data management solutions. All these factors make data management solutions an important factor driving the growth of the global IVD quality control market.
For instance, with the introduction of new waters_connect for IVD and QUAN Review Application in May 2024, Waters Corporation simplified the clinical data review process. ExceptionFocused Review (xfR) enables users to quickly identify and address errors that require attention. Its key features include reducing data review time by up to 50% (in comparison to Waters TargetLyn Software) and providing a one-screen dashboard that summarizes key parameters like standards, calibration, and quality control, all grouped for a streamlined view.
North America is Dominating the IVD Quality Control Market
The global IVD quality control market is dominated by North American nations, especially the United States, for several important reasons, including the existence of several accredited clinical laboratories. The United States boasts a well-respected healthcare system and many accredited clinical laboratories that follow tight quality control guidelines. The healthcare systems in North America have embraced cutting-edge diagnostic technologies like immunoassays and molecular diagnostics with great speed. The requirement for quality control procedures to guarantee the precision and dependability of test results has increased because of the growing usage of these technologies.
For example, Next Gen Diagnostics announced on June 11, 2024, that it would open its first laboratory in the United States in Cambridge, Massachusetts. The facility will offer United States customers and partners fully integrated, affordable bacterial sequencing and bioinformatics services. This ability is enhanced by NGD's best-in-class fully automated bioinformatics, which offers comprehensive analysis of cohort phylogeny, resistance elements, and phenotype, delivered and visualized in a robust user interface, as well as quality control and relatedness determination validated in several publications.
Future Market Scenario (2024-2031F)
The global IVD quality control market is expected to see a rise in demand for multi-analyte controls, which contain numerous analytes of interest.
Point-of-care testing adoption in the global IVD quality control market is motivated by the need for quick, easy-to-use, and trustworthy diagnostic tools that improve patient outcomes and expedite processes.
It is anticipated that the increased focus on developing environmentally friendly and sustainable products will drive the growth of the global IVD quality control market.
In the global IVD quality control market, companion diagnostics, which direct the use of particular treatment products, are becoming increasingly popular.
Key Players Landscape and Outlook
Many major companies in the global IVD quality control market are forming alliances to expand in the industry. Major players can build more sophisticated and comprehensive quality control products by collaborating with other businesses to make use of complementary skills, technology, and resources. Through alliances, prominent players can better serve the different needs of the diagnostics industry by broadening the scope of their quality control solutions and diversifying their product portfolios. Investing heavily in R&D and obtaining regulatory licenses is necessary to develop products with quality control.
For example, top AI software provider Bioz, Inc., dedicated to scientific research, announced in January 2024 that it has partnered with top worldwide diagnostics provider Randox Laboratories Ltd. The organization, which is well-known for its creative research and development, provides a wide range of superior goods and services, such as quality controls, toxicology solutions, modern diagnostic devices, and clinical chemistry reagents. Using this creative partnership, Bioz has integrated Bioz Badges as dynamic, real-time widgets into the product pages of Randox Laboratories' website. These widgets offer real-time scientific application data, including excerpts from peer-reviewed scientific articles that are specifically connected to the use of the product. This collaboration aims to help academics make evidence-based decisions by raising exposure and brand awareness.

1. Research Methodology
2. Project Scope and Definitions
3. Executive Summary
4. Global IVD Quality Control Market Outlook, 2017-2031F
4.1. Market Size & Forecast
4.1.1. By Value
4.1.2. By Volume
4.2. By Product
4.2.1. By Source
4.2.1.1. Plasma
4.2.1.2. Whole Blood
4.2.1.3. Urine
4.2.2. Quality Control Products
4.2.2.1. By Function
4.2.2.1.1. Instrument-Specific Controls
4.2.2.1.2. Independent Controls
4.2.2.2. By Type
4.2.2.2.1. Serum/Plasma-based Controls
4.2.2.2.2. Whole Blood-based Controls
4.2.2.2.3. Urine-based Controls
4.2.2.2.4. Others
4.2.3. Data Management Solutions
4.2.4. Quality Assessment Services
4.3. By Application
4.3.1. Oncology
4.3.2. Cardiology
4.3.3. Neurology
4.3.4. Infectious Diseases
4.3.5. Autoimmune Disorders
4.3.6. Others
4.4. By Technique
4.4.1. Molecular Diagnostics
4.4.2. Coagulation/Hemostasis
4.4.3. Hematology
4.4.4. Microbiology
4.4.5. Immunochemistry/Immunoassay
4.4.6. Clinical Chemistry/Biochemistry
4.4.7. Others
4.5. By End-user
4.5.1. Hospitals and Clinics
4.5.2. Diagnostic Laboratories
4.5.3. IVD Manufacturers
4.5.4. CROs
4.5.5. Others
4.6. By Region
4.6.1. North America
4.6.2. Europe
4.6.3. Asia-Pacific
4.6.4. South America
4.6.5. Middle East and Africa
4.7. By Company Market Share (%), 2023
5. Global IVD Quality Control Market Outlook, By Region, 2017-2031F
5.1. North America*
5.1.1. Market Size & Forecast
5.1.1.1. By Value
5.1.1.2. By Volume
5.1.2. By Source
5.1.2.1. Plasma
5.1.2.2. Whole Blood
5.1.2.3. Urine
5.1.3. By Product
5.1.3.1. Quality Control Products
5.1.3.1.1. By Function
5.1.3.1.1.1. Instrument-Specific Controls
5.1.3.1.1.2. Independent Controls
5.1.3.1.2. By Type
5.1.3.1.2.1. Serum/Plasma-based Controls
5.1.3.1.2.2. Whole Blood-based Controls
5.1.3.1.2.3. Urine-based Controls
5.1.3.1.2.4. Others
5.1.3.2. Data Management Solutions
5.1.3.3. Quality Assessment Services
5.1.4. By Application
5.1.4.1. Oncology
5.1.4.2. Cardiology
5.1.4.3. Neurology
5.1.4.4. Infectious Diseases
5.1.4.5. Autoimmune Disorders
5.1.4.6. Others
5.1.5. By Technique
5.1.5.1. Molecular Diagnostics
5.1.5.2. Coagulation/Hemostasis
5.1.5.3. Hematology
5.1.5.4. Microbiology
5.1.5.5. Immunochemistry/Immunoassay
5.1.5.6. Clinical Chemistry/Biochemistry
5.1.5.7. Others
5.1.6. By End-user
5.1.6.1. Hospitals and Clinics
5.1.6.2. Diagnostic Laboratories
5.1.6.3. IVD Manufacturers
5.1.6.4. CROs
5.1.6.5. Others
5.1.7. United States*
5.1.7.1. Market Size & Forecast
5.1.7.1.1. By Value
5.1.7.1.2. By Volume
5.1.7.2. By Source
5.1.7.2.1. Plasma
5.1.7.2.2. Whole Blood
5.1.7.2.3. Urine
5.1.7.3. By Product
5.1.7.3.1. Quality Control Products
5.1.7.3.1.1. By Function
5.1.7.3.1.1.1. Instrument-Specific Controls
5.1.7.3.1.1.2. Independent Controls
5.1.7.3.2. By Type
5.1.7.3.2.1.1. Serum/Plasma-based Controls
5.1.7.3.2.1.2. Whole Blood-based Controls
5.1.7.3.2.1.3. Urine-based Controls
5.1.7.3.2.1.4. Others
5.1.7.3.3. Data Management Solutions
5.1.7.3.4. Quality Assessment Services
5.1.7.4. By Application
5.1.7.4.1. Oncology
5.1.7.4.2. Cardiology
5.1.7.4.3. Neurology
5.1.7.4.4. Infectious Diseases
5.1.7.4.5. Autoimmune Disorders
5.1.7.4.6. Others
5.1.7.5. By Technique
5.1.7.5.1. Molecular Diagnostics
5.1.7.5.2. Coagulation/Hemostasis
5.1.7.5.3. Hematology
5.1.7.5.4. Microbiology
5.1.7.5.5. Immunochemistry/Immunoassay
5.1.7.5.6. Clinical Chemistry/Biochemistry
5.1.7.5.7. Others
5.1.7.6. By End-user
5.1.7.6.1. Hospitals and Clinics
5.1.7.6.2. Diagnostic Laboratories
5.1.7.6.3. IVD Manufacturers
5.1.7.6.4. CROs
5.1.7.6.5. Others
5.1.8. Canada
5.1.9. Mexico
*All segments will be provided for all regions and countries covered
5.2. Europe
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. United Kingdom
5.2.5. Russia
5.2.6. Netherlands
5.2.7. Spain
5.2.8. Turkey
5.2.9. Poland
5.3. Asia-Pacific
5.3.1. India
5.3.2. China
5.3.3. Japan
5.3.4. Australia
5.3.5. Vietnam
5.3.6. South Korea
5.3.7. Indonesia
5.3.8. Philippines
5.4. South America
5.4.1. Brazil
5.4.2. Argentina
5.5. Middle East and Africa
5.5.1. Saudi Arabia
5.5.2. UAE
5.5.3. South Africa
6. Market Mapping, 2023
6.1. By Source
6.2. By Product
6.3. By Application
6.4. By Technique
6.5. By End-user
6.6. By Region
7. Macro Environment and Industry Structure
7.1. Demand Supply Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
7.4.1. Political Factors
7.4.2. Economic System
7.4.3. Social Implications
7.4.4. Technological Advancements
7.4.5. Environmental Impacts
7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter's Five Forces Analysis
7.5.1. Supplier Power
7.5.2. Buyer Power
7.5.3. Substitution Threat
7.5.4. Threat From New Entrant
7.5.5. Competitive Rivalry
8. Market Dynamics
8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)
9. Regulatory Framework and Innovation
9.1. Clinical Trials
9.2. Patent Landscape
9.3. Regulatory Approvals
9.4. Innovations/Emerging Technologies
10. Key Players Landscape
10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (By Value, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)
11. Pricing Analysis
12. Case Studies
13. Key Players Outlook
13.1. Bio-Rad Laboratories, Inc.
13.1.1. Company Details
13.1.2. Key Management Personnel
13.1.3. Products and Services
13.1.4. Financials (As Reported)
13.1.5. Key Market Focus and Geographical Presence
13.1.6. Recent Developments
13.2. Danaher Corporation
13.3. Thermo Fisher Scientific, Inc.
13.4. QuidelOrtho Corporation
13.5. Siemens Healthineers AG
13.6. LGC Group
13.7. Randox Laboratories Ltd.
13.8. Microbiologics, Inc.
13.9. Streck LLC
13.10. SERO AS
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
14. Strategic Recommendations
15. About Us & Disclaimer








  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $4500.00
  • $5700.00
  • $8200.00
  • ADD TO BASKET
  • BUY NOW